STOCK TITAN

[SCHEDULE 13G] Prothena Corporation plc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

ADAR1 Capital Management and related parties reported beneficial ownership of 3,375,009 ordinary shares of Prothena Corporation plc, representing 6.3% of the outstanding common stock as of June 30, 2025. The filing breaks the position into 2,892,995 shares held by ADAR1 Partners, LP and 482,014 shares held by Spearhead Insurance Solutions IDF, LLC. ADAR1 Capital Management, LLC reports shared voting and dispositive power over the full 3,375,009-share position. The filing cites 53,826,982 ordinary shares outstanding based on the Issuer's 10-Q filed August 4, 2025. The Schedule 13G is signed by Daniel Schneeberger on behalf of the reporting entities on August 14, 2025.

ADAR1 Capital Management e parti correlate hanno dichiarato la titolarità effettiva di 3.375.009 azioni ordinarie di Prothena Corporation plc, corrispondenti al 6,3% del capitale sociale in circolazione al 30 giugno 2025. La comunicazione suddivide la posizione in 2.892.995 azioni detenute da ADAR1 Partners, LP e 482.014 azioni detenute da Spearhead Insurance Solutions IDF, LLC. ADAR1 Capital Management, LLC dichiara di detenere in comune il potere di voto e il potere dispositiv o sull'intera posizione di 3.375.009 azioni. La segnalazione fa riferimento a 53.826.982 azioni ordinarie in circolazione, sulla base del Modulo 10-Q dell'emittente del 4 agosto 2025. Lo Schedule 13G è firmato da Daniel Schneeberger per conto delle entità segnalanti il 14 agosto 2025.

ADAR1 Capital Management y partes relacionadas informaron la propiedad beneficiaria de 3.375.009 acciones ordinarias de Prothena Corporation plc, que representan el 6,3% del capital social en circulación al 30 de junio de 2025. La presentación desglosa la posición en 2.892.995 acciones en manos de ADAR1 Partners, LP y 482.014 acciones en manos de Spearhead Insurance Solutions IDF, LLC. ADAR1 Capital Management, LLC declara tener poder compartido de voto y disposición sobre la totalidad de la posición de 3.375.009 acciones. La presentación cita 53.826.982 acciones ordinarias en circulación, según el Formulario 10-Q del emisor del 4 de agosto de 2025. El Schedule 13G está firmado por Daniel Schneeberger en nombre de las entidades informantes el 14 de agosto de 2025.

ADAR1 Capital Management 및 관련 당사자는 2025년 6월 30일 기준 Prothena Corporation plc의 보통주 3,375,009주(발행주식의 6.3%)에 대한 실질 보유를 보고했습니다. 제출 서류는 해당 보유를 ADAR1 Partners, LP가 보유한 2,892,995주와 Spearhead Insurance Solutions IDF, LLC가 보유한 482,014주로 나누어 기재했습니다. ADAR1 Capital Management, LLC는 전체 3,375,009주에 대해 공동 의결권 및 처분권을 보유한다고 보고했습니다. 제출 서류는 발행회사가 2025년 8월 4일 제출한 10-Q를 근거로 발행된 보통주가 53,826,982주라고 명시하고 있습니다. Schedule 13G는 2025년 8월 14일 보고 기관들을 대표하여 Daniel Schneeberger가 서명했습니다.

ADAR1 Capital Management et des parties liées ont déclaré la propriété bénéficiaire de 3 375 009 actions ordinaires de Prothena Corporation plc, soit 6,3 % du capital social en circulation au 30 juin 2025. Le dépôt ventile la position en 2 892 995 actions détenues par ADAR1 Partners, LP et 482 014 actions détenues par Spearhead Insurance Solutions IDF, LLC. ADAR1 Capital Management, LLC déclare exercer conjointement le pouvoir de vote et le pouvoir dispositif sur l'intégralité de la position de 3 375 009 actions. Le dépôt fait état de 53 826 982 actions ordinaires en circulation, d'après le formulaire 10-Q de l'émetteur daté du 4 août 2025. Le Schedule 13G est signé par Daniel Schneeberger au nom des entités déclarantes le 14 août 2025.

ADAR1 Capital Management und verbundene Parteien meldeten den wirtschaftlichen Besitz von 3.375.009 Stammaktien der Prothena Corporation plc, was 6,3% des ausstehenden Stammkapitals zum 30. Juni 2025 entspricht. Die Meldung teilt die Position auf in 2.892.995 Aktien, gehalten von ADAR1 Partners, LP, und 482.014 Aktien, gehalten von Spearhead Insurance Solutions IDF, LLC. ADAR1 Capital Management, LLC gibt an, über die gesamten 3.375.009 Aktien gemeinsames Stimm- und Verfügungsrecht zu haben. In der Meldung werden 53.826.982 ausstehende Stammaktien genannt, basierend auf dem vom Emittenten am 4. August 2025 eingereichten 10-Q. Das Schedule 13G ist am 14. August 2025 von Daniel Schneeberger im Namen der meldenden Einheiten unterzeichnet worden.

Positive
  • Material stake disclosed: Reports beneficial ownership of 3,375,009 shares (6.3%), which is a significant, reportable position.
  • Transparency among affiliates: Filing details allocation between ADAR1 Partners, LP (2,892,995 shares) and Spearhead Insurance Solutions IDF, LLC (482,014 shares) and includes a Joint Filing Agreement.
  • Clear classification: Filed on Schedule 13G with a certification stating holdings are in the ordinary course of business and not intended to influence control.
Negative
  • None.

Insights

TL;DR: ADAR1 group disclosed a passive 6.3% stake (3.375M shares) in PRTA, filed on Schedule 13G, indicating non-control intent.

The filing reports a combined beneficial ownership of 3,375,009 ordinary shares, representing 6.3% of Prothena's 53,826,982 shares outstanding. The cover page allocation shows 2,892,995 shares held by ADAR1 Partners, LP and 482,014 shares held by Spearhead Insurance Solutions IDF, LLC. ADAR1 Capital Management, LLC states shared voting and dispositive power; the Schedule 13G classification and the certification language indicate the position is held in the ordinary course of business and not for control. For investors, this disclosure provides clarity on a meaningful passive holder but contains no operational or financial projections.

TL;DR: This is a standard Schedule 13G passive ownership disclosure showing shared control among affiliated entities and an individual.

The document identifies three reporting persons: ADAR1 Capital Management, LLC (investment adviser), ADAR1 Capital Management GP, LLC (general partner), and Daniel Schneeberger (manager/individual). The filing attributes shared voting and dispositive power over the reported shares to the adviser and related entities. The Schedule 13G classification and the signed certification assert the holdings were not acquired to influence control. The exhibit list includes a Joint Filing Agreement, consistent with coordinated reporting among affiliates.

ADAR1 Capital Management e parti correlate hanno dichiarato la titolarità effettiva di 3.375.009 azioni ordinarie di Prothena Corporation plc, corrispondenti al 6,3% del capitale sociale in circolazione al 30 giugno 2025. La comunicazione suddivide la posizione in 2.892.995 azioni detenute da ADAR1 Partners, LP e 482.014 azioni detenute da Spearhead Insurance Solutions IDF, LLC. ADAR1 Capital Management, LLC dichiara di detenere in comune il potere di voto e il potere dispositiv o sull'intera posizione di 3.375.009 azioni. La segnalazione fa riferimento a 53.826.982 azioni ordinarie in circolazione, sulla base del Modulo 10-Q dell'emittente del 4 agosto 2025. Lo Schedule 13G è firmato da Daniel Schneeberger per conto delle entità segnalanti il 14 agosto 2025.

ADAR1 Capital Management y partes relacionadas informaron la propiedad beneficiaria de 3.375.009 acciones ordinarias de Prothena Corporation plc, que representan el 6,3% del capital social en circulación al 30 de junio de 2025. La presentación desglosa la posición en 2.892.995 acciones en manos de ADAR1 Partners, LP y 482.014 acciones en manos de Spearhead Insurance Solutions IDF, LLC. ADAR1 Capital Management, LLC declara tener poder compartido de voto y disposición sobre la totalidad de la posición de 3.375.009 acciones. La presentación cita 53.826.982 acciones ordinarias en circulación, según el Formulario 10-Q del emisor del 4 de agosto de 2025. El Schedule 13G está firmado por Daniel Schneeberger en nombre de las entidades informantes el 14 de agosto de 2025.

ADAR1 Capital Management 및 관련 당사자는 2025년 6월 30일 기준 Prothena Corporation plc의 보통주 3,375,009주(발행주식의 6.3%)에 대한 실질 보유를 보고했습니다. 제출 서류는 해당 보유를 ADAR1 Partners, LP가 보유한 2,892,995주와 Spearhead Insurance Solutions IDF, LLC가 보유한 482,014주로 나누어 기재했습니다. ADAR1 Capital Management, LLC는 전체 3,375,009주에 대해 공동 의결권 및 처분권을 보유한다고 보고했습니다. 제출 서류는 발행회사가 2025년 8월 4일 제출한 10-Q를 근거로 발행된 보통주가 53,826,982주라고 명시하고 있습니다. Schedule 13G는 2025년 8월 14일 보고 기관들을 대표하여 Daniel Schneeberger가 서명했습니다.

ADAR1 Capital Management et des parties liées ont déclaré la propriété bénéficiaire de 3 375 009 actions ordinaires de Prothena Corporation plc, soit 6,3 % du capital social en circulation au 30 juin 2025. Le dépôt ventile la position en 2 892 995 actions détenues par ADAR1 Partners, LP et 482 014 actions détenues par Spearhead Insurance Solutions IDF, LLC. ADAR1 Capital Management, LLC déclare exercer conjointement le pouvoir de vote et le pouvoir dispositif sur l'intégralité de la position de 3 375 009 actions. Le dépôt fait état de 53 826 982 actions ordinaires en circulation, d'après le formulaire 10-Q de l'émetteur daté du 4 août 2025. Le Schedule 13G est signé par Daniel Schneeberger au nom des entités déclarantes le 14 août 2025.

ADAR1 Capital Management und verbundene Parteien meldeten den wirtschaftlichen Besitz von 3.375.009 Stammaktien der Prothena Corporation plc, was 6,3% des ausstehenden Stammkapitals zum 30. Juni 2025 entspricht. Die Meldung teilt die Position auf in 2.892.995 Aktien, gehalten von ADAR1 Partners, LP, und 482.014 Aktien, gehalten von Spearhead Insurance Solutions IDF, LLC. ADAR1 Capital Management, LLC gibt an, über die gesamten 3.375.009 Aktien gemeinsames Stimm- und Verfügungsrecht zu haben. In der Meldung werden 53.826.982 ausstehende Stammaktien genannt, basierend auf dem vom Emittenten am 4. August 2025 eingereichten 10-Q. Das Schedule 13G ist am 14. August 2025 von Daniel Schneeberger im Namen der meldenden Einheiten unterzeichnet worden.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Includes (i) 2,892,995 ordinary shares, par value $0.01 per share ("Ordinary Shares") held by ADAR1 Partners, LP and (ii) 482,014 ordinary shares held by Spearhead Insurance Solutions IDF, LLC as of June 30, 2025. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 53,826,982 ordinary shares of Prothena Corporation Public Limited Company (the "Issuer") outstanding as of June 30, 2025 reported in the Issuer's 10-Q, filed with the SEC on August 4, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 2,892,995 ordinary shares, $0.01 per share ("Ordinary Shares") held by ADAR1 Partners, LP as of June 30, 2025. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 53,826,982 ordinary shares of Prothena Corporation Public Limited Company (the "Issuer") outstanding as of June 30, 2025 reported in the Issuer's 10-Q, filed with the SEC on August 4, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes (i) 2,892,995 ordinary shares, par value $0.01 per share ("Ordinary Shares") held by ADAR1 Partners, LP and (ii) 482,014 ordinary shares held by Spearhead Insurance Solutions IDF, LLC as of June 30, 2025. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 53,826,982 ordinary shares of Prothena Corporation Public Limited Company (the "Issuer") outstanding as of June 30, 2025 reported in the Issuer's 10-Q, filed with the SEC on August 4, 2025.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:08/14/2025
ADAR1 Capital Management GP, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:08/14/2025
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:08/14/2025
Exhibit Information

Exhibit A: Joint Filing Agreement

FAQ

What stake in Prothena (PRTA) does ADAR1 report?

The reporting persons disclose beneficial ownership of 3,375,009 ordinary shares, equal to 6.3% of outstanding shares as of June 30, 2025.

How are the 3,375,009 shares allocated among ADAR1-related entities?

2,892,995 shares are held by ADAR1 Partners, LP and 482,014 shares are held by Spearhead Insurance Solutions IDF, LLC.

Does the filing indicate ADAR1 seeks control of Prothena?

No. The Schedule 13G certification states the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control.

What voting and dispositive power is reported?

ADAR1 Capital Management, LLC reports 0 sole voting/dispositive power and 3,375,009 shared voting and shared dispositive power over the shares.

What outstanding share count is the percent ownership based on?

The percent is calculated using 53,826,982 ordinary shares outstanding as reported in the Issuer's 10-Q filed August 4, 2025.
Prothena

NASDAQ:PRTA

PRTA Rankings

PRTA Latest News

PRTA Latest SEC Filings

PRTA Stock Data

405.88M
42.97M
19.58%
74.3%
8.84%
Biotechnology
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2